BayWa AG's Board of Management, with the approval of the Supervisory Board, has decided to proceed with the second tranche of its capital increase as part of the company's ongoing restructuring plan.
In the first tranche, major shareholders Bayerische Raiffeisen-Beteiligungs-Aktiengesellschaft (BRB) and Raiffeisen Agrar Invest AG (RAI) subscribed to new shares worth approximately €125 million.
For the second tranche, the subscription price is set at €2.79 per new share, with a subscription ratio of one existing share entitling the holder to two new shares. BayWa shareholders, excluding anchor shareholders BRB and RAI, are entitled to subscribe for up to 27,368,508 new shares. An additional 92,070 shares that were not taken up during the first tranche will be offered to the major shareholders.
The anchor shareholders have committed to participating in the second tranche, ensuring that BayWa AG raises at least €25 million in this round. Including both tranches, the total gross proceeds are expected to fall between €150 million and €201.6 million.
The German Federal Financial Supervisory Authority (BaFin) approved the required securities prospectus on 24 October 2025. Subscription rights will be granted through Baader Bank Aktiengesellschaft, with the subscription period running from 28 October to 10 November 2025. These rights will be tradable on the Frankfurt Stock Exchange from 28 October to 5 November 2025. The capital increase is expected to be completed by mid-November.
No compensation will be provided for unexercised subscription rights. Any shares not subscribed for during the period may be placed privately with qualified investors or sold on the market, at a price no lower than the subscription price.
The capital increase forms part of BayWa AG's restructuring plan, confirmed by the restructuring court under StaRUG, and provides for the issue of up to 72,263,446 new shares in total. The securities prospectus is available on BayWa AG's website under "Capital Increase 2025."
To view the full report, click here.
© BayWaFor more information:
Dr. Frank Herkenhoff
BayWa AG
Tel: +49 899 2223 680
Email: [email protected]
www.baywa.com
